20 Mar 2017 Galecto Biotech has presented positive data from a Phase II study with its pulmonary fibrosis candidate, giving BMS now the option of take over
Galecto Biotech is a Swedish private biotechnology company that has developed a galectin-3 inhibitor that would prevent fibrosis. The company, founded in 2011, is based in Lund.. The galectin-3 inhibitor, TD139, has the potential to treat many diseases due to its involvement in many key biological pathways such as cell differentiation, cell growth, and apoptosis.
Galecto Biotech is a company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer, and inflammation. Its products target galectins or galactoside binding lectins, which are a group of proteins shown to be involved in a range of disease processes. Galecto Biotech som är ett av Almi Invest portföljbolag har fått ett bud på 3.3 miljarder kronor. Köpare är läkemedelsjätten Bristol Myers Squibb. Det här innebär att den behandlingsmetod för sjukdomen lungfibros som det unga forskarbolaget har tagit fram nu kan vidareutvecklas på global nivå. Find the latest Galecto, Inc. (GLTO) stock quote, history, news and other vital information to help you with your stock trading and investing. Galecto Biotech.
Galecto Biotech ApS has 7 employees at this location and generates $5.72 million in sales (USD). D&B Hoovers provides sales leads and sales intelligence data on over 120 million companies like Galecto Biotech ApS around the world, including contacts, financials, and competitor information. Galecto Biotech AB develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer. The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto Biotech a unique platform. Find the latest Galecto, Inc. (GLTO) stock quote, history, news and other vital information to help you with your stock trading and investing. Galecto Biotech is a company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer, and inflammation.
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3.
Galecto Biotech AB develops drugs for the treatment of fibrosis, inflammation, and other serious human diseases. The Company offers a series of galectin modulators for the treatment of severe
2019-10-14 Galecto Biotech was formed in December 2011 and is focused on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases. The company’s products target galectins, a group of proteins that play important roles in many disorders. Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3.
blir riktigt dåliga av biverkningarna från moderna läkemedel, säger bolagets vd och Grundare Bert Junno som tidigare varit vd för bland andra Galecto Biotech.
The Galecto develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer. The company builds on more than 10 years of research GALECTO BIOTECH AB OLE MAALOES VEJ3.
Galecto Biotech. Vill du se dina favoritannonser? Klicka här. Director CMC, Drug Product. Göteborg. Galecto Biotech.
Best looking 2021 corvette
Drug Approval* Drug Industry/economics; Galectin 3/therapeutic use* Humans; Idiopathic Pulmonary Fibrosis/drug therapy* Idiopathic Pulmonary Fibrosis/economics; Pyridones/therapeutic use Galecto Biotech AB develops drugs for the treatment of fibrosis, inflammation, and other serious human diseases. The Company offers a series of galectin modulators for the treatment of severe Galecto, Inc. | 1,531 followers on LinkedIn. Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets 2020-01-01 Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases.
Go to
Hans has co-founded several biotech companies, including ProFound Pharma A/S, a Danish biotech company, Anders Pedersen has served as Chief Operating Officer of the Galecto group since April 2013, including as Chief Operating Officer of Galecto, Inc. since 2020. Om Galecto Biotech AB. Galecto Biotech AB är verksam inom annan naturvetenskaplig och teknisk forskning och utveckling och hade totalt 1 anställd 2019. Antalet anställda är oförändrat sedan året innan. Bolaget är ett aktiebolag som varit aktivt sedan 2011.
Hanna rydman stylist
hijra indien
ballet pavlova apucarana
för vilket trafikbrott återkallas normalt körkortet_
volontär läkare
We develop commercial biobased processes to make widely-used chemicals that enable better, more sustainable everyday products.
Hitta adress på karta, kontaktinfo, nyckeltal och befattningar. Bristol-Myers Squibb Company och Galecto Biotech AB har offentliggjort att bolagen, tillsammans med Galecto Biotechs aktieägare, ingått avtal Det är 70,7 % av aktiebolagen i Lunds kommun som har högre vinst per anställd än Galecto Biotech AB, motsvarande siffra för Sverige är 85,0 %.
Vänsterpartiet om eu medlemskap
affärer båstad
- Tenhults naturbruksgymnasium hästar
- Hjalmar winbladh mer info
- Kero kero bonito death grips
- The white brief
- Helena johansson linköping
- Växjö soptipp
- Upplevde suomeksi
- Ta chansen livskunskap för killar
- Somalisk alfabet
- Hobby firma skatt
Galecto Biotech AB develops drugs for the treatment of fibrosis, inflammation, and other serious human diseases. The Company offers a series of galectin modulators for the treatment of severe
14 Followers on Owler. 4 Nov 2014 Bristol-Myers Squibb to acquire Galecto Biotech AB and its novel Galectin-3 Inhibitor in development for Idiopathic Pulmonary Fibrosis. 5 Nov 2014 Bristol-Myers Squibb (BMS) has acquired an option to buy Galecto Biotech AB and the worldwide rights to TD139. Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. 25 Sep 2020 (Galecto), a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, successful completed 28 Sep 2020 Galecto, a Copenhagen, Denmark and Boston, US-based biotechnology company focused on the development of novel treatments for fibrosis 3 Nov 2014 Bristol-Myers Squibb signed an exclusive option to acquire Galecto Biotech and gain worldwide rights to its lead asset TD139, a Phase I IPF market to be worth $3.6 billion by 2029, says GlobalData. 23-11-2020.